Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ethan Geiger

Physician Assistant Waco, TX Physician Assistant

NPI 1992210710 CMS profile 10807323

321 Richland West Cir, Waco, TX 76712

Open in the dashboard

General payments

$12,383

586 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ethan Geiger of Waco, TX is reported in the CMS Open Payments database as having received $12,383 across 586 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,187 77
2024 General $2,308 115
2023 General $2,616 111
2022 General $2,696 131
2021 General $3,576 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ethan Geiger
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ethan Geiger were reported at $1,187. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ethan Geiger Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,576 $132 $37–$438 $132
2022 $2,696 $155 $48–$522 $149
2023 $2,616 $167 $52–$557 $160
2024 $2,308 $178 $55–$600 $164
2025 $1,187 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,527 88 payments
  2. Medtronic, Inc. $1,351 33 payments
  3. Novartis Pharmaceuticals Corporation $937 98 payments
  4. AstraZeneca Pharmaceuticals LP $828 43 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $797 39 payments
  6. Merck Sharp & Dohme Corporation $765 38 payments
  7. Abbott Laboratories $741 12 payments
  8. Amgen Inc. $660 31 payments
  9. Novo Nordisk Inc $600 24 payments
  10. E.R. Squibb & Sons, L.L.C. $557 33 payments
  11. Other $3,620 147 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,363 585 payments
  2. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. LifeVest $1,527 88 payments
  2. VERQUVO $861 43 payments
  3. FARXIGA $726 38 payments
  4. JARDIANCE $696 35 payments
  5. RYBELSUS $600 24 payments
  6. LEQVIO $573 71 payments
  7. COREVALVE EVOLUT R $539 15 payments
  8. XARELTO $520 24 payments
  9. Repatha $510 25 payments
  10. Ozempic $491 23 payments
  11. Other $7,289 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

3,548

Median for Physician Assistant: 241

Drug cost

$504,919

Median for Physician Assistant: $4,110

Branded share of claims

25.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 194 $159,135
Jardiance Empagliflozin Brand 81 $64,313
Entresto Sacubitril/Valsartan Brand 50 $57,340
Repatha Sureclick Evolocumab Brand 51 $41,270
Farxiga Dapagliflozin Propanediol Brand 44 $39,181
Ozempic Semaglutide Brand 30 $29,100
Multaq Dronedarone Hcl Brand 23 $19,530
Praluent Pen Alirocumab Brand 23 $15,427
Xarelto Rivaroxaban Brand 13 $14,672
Brilinta Ticagrelor Brand 15 $14,479

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$5,564

Medicare's payments for the services billed

Medicare patients

52

Average age 74

Services billed

98

27 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 42%
Diabetes 38%
Arthritis 38%
Atrial fibrillation 37%
Chronic kidney disease 27%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$226 — —
Repatha
$188 51 —
FARXIGA
$149 44 —
VERQUVO
$96 — —
ELIQUIS
$85 194 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

586 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record